Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Now available on-demand! Cracking the code: learnings from oligonucleotide method development WATCH NOW

The challenges of large molecule bioanalysis by LC–MS: an interview with Rob Wheller

16 May 2018
Interviews Large molecules MS (LC–MS/MS, HRMS, IMS)

Rob Wheller, Principal Scientist from LGC (Fordham, UK), discusses his current research focuses; the advantages, disadvantages and challenges of the technologies he utilizes; and advice he would give to young, early-career scientists.

Interested in large molecule quantification? View our Spotlight for more resources

 

Related tags

expert interview LCMS LGC mass spectrometry
Previous article Next article

Related articles

17 JUL 2019 REGULATED BIOANALYSIS
Perspectives on the draft ICH M10 guidance: an interview with Eric Woolf
20 DEC 2019 INTERVIEWS
The importance of bioanalysis in clinical studies: an interview with Mark Bayliss
25 JUN 2019 INTERVIEWS
Advancing mass spectrometry technologies: an interview with Neil Walsh
12 JUN 2019 CLINICAL
Cell therapy: an interview with David Harris
26 JUN 2018 BIOMARKERS
Novel ADME biomarkers and HRMS move new medicines to patients faster
20 MAR 2018 DATA PROCESSING AND INTERPRETATION
An introduction to mass spectrometry with Scott Summerfield
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone